Emisphere Technologies, Inc.   Report issue

For profit Phase 1
Founded: Roseland NJ United States (1986)
Status: Acquired by Novo Nordisk (2020)

Organization Overview

First Clinical Trial
2001
NCT00982254
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Emisphere Technologies, Inc.

Active Ingredients

Drugs in Phase 1 Trials (1)

insulin human (humulin) (1 trial)

Drugs in Other Trials (1)

cyanocobalamin (berocca) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus, Type 2 (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 2